Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Sunshine Union Hospital, Weifang, Shandong, China.
Ann Hematol. 2023 Sep;102(9):2403-2412. doi: 10.1007/s00277-023-05274-7. Epub 2023 May 20.
Detection of bone marrow involvement (BMI) for patients with follicular lymphoma (FL) is of great significance for staging and treatment. The clinical value of positron emission tomography/computed tomography (PET/CT) in assessing BMI is still under debate and investigation. PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched to identify studies evaluating PET/CT in detecting BMI in FL patients. Data extraction and quality evaluation were independently conducted by two reviewers, and nine eligible studies were selected as final quantitative analysis. Nine studies comprising 1119 FL patients were included. The pooled sensitivity was 0.67 (95% CI, 0.38-0.87), and the pooled specificity was 0.82 (95% CI, 0.75-0.87). The pooled positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 3.7 (95% CI, 2.1-6.3), 0.4 (95% CI, 0.18-0.91), and 9 (95% CI, 2-33), respectively. The area under the curve of PET/CT to detect BMI in FL patients was 0.83 (95% CI, 0.8-0.86). Current evidence suggests that PET/CT cannot replace bone marrow biopsy to detect BMI, but it is still of partial clinical significance for the prognosis of patients with follicular lymphoma.
检测滤泡性淋巴瘤(FL)患者的骨髓受累(BMI)对于分期和治疗具有重要意义。正电子发射断层扫描/计算机断层扫描(PET/CT)在评估 BMI 中的临床价值仍存在争议和研究。我们系统地检索了 PubMed、Embase、Web of Science 和 Cochrane Library 数据库,以确定评估 PET/CT 检测 FL 患者 BMI 的研究。两名评审员独立进行数据提取和质量评估,选择了 9 项符合条件的研究进行最终定量分析。9 项研究共纳入 1119 例 FL 患者。汇总敏感性为 0.67(95%CI,0.38-0.87),汇总特异性为 0.82(95%CI,0.75-0.87)。汇总阳性似然比、阴性似然比和诊断比值比分别为 3.7(95%CI,2.1-6.3)、0.4(95%CI,0.18-0.91)和 9(95%CI,2-33)。PET/CT 检测 FL 患者 BMI 的曲线下面积为 0.83(95%CI,0.8-0.86)。现有证据表明,PET/CT 不能替代骨髓活检来检测 BMI,但对于滤泡性淋巴瘤患者的预后仍具有一定的临床意义。